Notícias e Atividades da Rein Therapeutics

Rein Therapeutics é uma empresa listada sob o símbolo ALRN (US).

Fusão, aquisição e financiamento envolvendo Rein Therapeutics.

• O novo nome de Rein Therapeutics é Rein Therapeutics. (publicado em 13 de janeiro de 2025).
• Rein Therapeutics adquiriu Lung Therapeutics (publicado em 1 de novembro de 2023).

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Rein Therapeutics

• Brian Windsor, Director, President and Chief Executive Officer
• Reinhard Ambros, Director
• Josef Von Rickenbach, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da Rein Therapeutics.

Rein Therapeutics possui 2.339 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Biogen (Estados Unidos).

Popular M&A news in Biotecnologia

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (publicado em 30 de abril de 2025)..
• Deepull acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de abril de 2025).
• Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Herriot Tabuteau - Chief Executive Officer and Director da Axsome Therapeutics
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Rein Therapeutics

• Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
• Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
• Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
• Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
• Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
• Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
• Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
• Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
• Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
• Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
• View more press releases Close

Redes sociais sobre Rein Therapeutics

• Rein Therapeutics na Wikipedia, Google News e Yahoo Finance
• Rein Therapeutics na LinkedIn, Twitter e YouTube